Uscom (ASX:UCM) - Executive Chairman & CEO, Rob Phillips
Executive Chairman & CEO, Rob Phillips
Sourced: Uscom
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Uscom (UCM) has partnered with the University of Tasmania for the IDEAL study funded by the National Health and Medical Research Council
  • This eHealth study has been given a $1 million grant to develop better methods for managing heart health in Australia
  • Part of this study includes Uscom’s BP+ blood pressure sensor
  • BP+ is set to replace conventional blood pressure monitors and is already being used by major organisations and universities across the world
  • The IDEAL study includes examining patients with BP+ and conducting a cardiovascular risk assessment
  • Data will then be sent off to the University of Tasmania for analysis
  • Uscom is down a slight 3.39 per cent and shares are trading for 28.5 cents each

Uscom (UCM) has partnered with the University of Tasmania as part of the IDEAL study funded by the National Health and Medical Research Council (NHMRC).

The IDEAL study is supported by a $1 million NHMRC grant to develop better methods for monitoring cardiovascular health in Australia. The eHealth study includes the Uscom BP+ as the front-end blood pressure sensor.

The International Society of Hypertension estimates the global cost of uncontrolled blood pressure is over $500 billion. The IDEAL study is targeting the benefits of early detection and improved management of heart disease using Uscom BP+.

Essentially, Uscom BP+ is a highly-accurate blood pressure monitor which measures blood pressure waveforms at the heart as well as in the arm. It is set to replace conventional blood pressure monitors and is the up-and-coming standard of care measurement for hypertension, heart failure and general heart health.

“Uscom has invested the last 15 years of product development in optimising core sensors and now has sector-leading digital technologies that are ‘ideal’ for monitoring cardiac, vascular and pulmonary care,” Executive Chairman and CEO Professor Rob Phillips said.

Along with the University of Tasmania, the collaboration includes: the Menzies Institute, the National Heart Foundation, the Department of Health Tasmania, Primary Health Tasmania and Healthcare Software.

Furthermore, Uscom BP+ is being used by researchers at the Imperial College, University College and Great Ormond Street Hospital in London, The University of Mons in Belgium, The University of Pennsylvania and Colombia University in the U.S., Auckland University, and other large U.S.-based technology companies.

The IDEAL study will include examining patients with BP+ as well as conducting a cardiovascular risk assessment. This involves a risk profile questionnaire, a blood sample collection and a cholesterol assessment.

The data will then be recorded and then transferred to the University of Tasmania database for analysis.

The Uscom BP+ has CE and TGA approval, and is progressing through Chinese NMPA and U.S. FDA regulatory processes. The device is expected to be released internationally in 2020.

“The potential mortality, morbidity and cost savings in getting eHealth right are almost inestimable, and BP+ is an emerging device in that new health practice,” Rob added.

Uscom is down a slight 3.39 per cent and shares are trading for 28.5 cents each at 3:52 pm AEST.

UCM by the numbers
More From The Market Herald
Genetic Technologies (ASX:GTG) - CEO, Simon Morriss

" Genetic Technologies (ASX:GTG) expands EasyDNA into Indian and European markets

Genetic Technologies (ASX:GTG) has embarked on a significant expansion of its recently acquired at-home DNA testing…
The Market Herald Video

" PainChek (ASX:PCK) to receive govt funding for children’s disability app

PainChek (ASX:PCK) has been awarded a $392,820 grant from the Western Australia State Government's Future Health…
The Market Herald Video

" Prescient Therapeutics (ASX:PTX) granted key US patent for OmniCar platform

Prescient Therapeutics (ASX:PTX) has been granted a key US patent for its OmniCAR universal immune receptor…

" Antisense Therapeutics (ASX:ANP) dosing of muscular dystrophy drug on hold

Antisense Therapeutics (ASX:ANP) applies for partial clinical hold that limits dosing of its drug for muscular…